Clinical Trial Update: Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial evaluating tasimelteon, a melatonin receptor agonist, versus placebo in adults with major depressive disorder has completed and resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Tasimelteon (tasimelteon)

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Major Depressive Disorder | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2015-06-19